GLOW vs KLOW: What Is the Difference Between the Peptide Blends?
GLOW and KLOW are peptide blend names, and the difference is one peptide: KLOW is GLOW with KPV added. GLOW holds GHK-Cu, BPC-157 and TB-500. Neither name is a standard formula, so vials sold under the same four letters can differ between suppliers; Australian Research Peptides states what is in each of its own. No published study has tested either blend as supplied. Supplied to laboratories and researchers for in vitro research purposes only.
7 minute read
What Is the Difference Between GLOW and KLOW?
GLOW and KLOW are blend names, not single compounds, and the difference between them is one added peptide. KLOW holds everything GLOW holds, with KPV as a fourth component. Everything else about the two is shared.
The table below is built from this site’s own product records at build time, so it states what ARP actually lists rather than what the category generally does.
| Peptide | In GLOW | In KLOW |
|---|---|---|
| GHK-Cu | ~50 mg | ~50 mg |
| BPC-157 | ~10 mg | ~10 mg |
| TB-500 | ~10 mg | ~10 mg |
| KPV | Not in this blend | ~10 mg |
What Is GLOW?
GLOW is three peptides freeze-dried together into one sealed vial: BPC-157, TB-500 and GHK-Cu. Freeze-drying, or lyophilisation, removes the water and leaves a dry cake, which is why the three arrive as a single solid rather than as a mixture.
All three are studied in cell-signalling and extracellular-matrix research, and each carries its own separate literature. BPC-157 is a fifteen-amino-acid sequence derived from a gastric protein; TB-500 is the seven-residue actin-binding fragment of a larger protein called thymosin beta-4; and GHK-Cu is a human tripeptide — glycyl-L-histidyl-L-lysine — carrying a bound copper ion. Three molecules, three literatures, one vial.
Combining them in one container is a packaging decision. Nothing about drying three peptides together makes them a different compound, and nothing in the published record says three peptides sharing a vial behave differently from three kept apart.
What Is KLOW?
KLOW is those same three peptides with KPV added as a fourth. KPV is a chain of three amino acids — lysine, proline and valine — taken from the tail end of a larger signalling molecule called alpha-MSH.
KPV is what moves the vial across research fields. The other three sit in cell-signalling and extracellular-matrix research; the published work on KPV sits in inflammatory-signalling research. In cell-culture assays it is a substrate of the peptide transporter PepT1, which is a binding and transport fact about the molecule rather than a claim about anything it does.
Do the Names GLOW and KLOW Define a Standard Formula?
No. GLOW and KLOW are market labels used across this category, not specifications, so two vials sold under the same name can hold different peptides in different amounts. There is no registry, no monograph and no body that defines either word.
This is the most useful thing to know before comparing suppliers. A price difference between two products called KLOW may be a difference in what is in the vial rather than a difference in value. Read the compound list and the milligram total, never the four letters. A supplier who will not itemise the vial has not said what it contains.
Are GLOW and KLOW Single Peptides?
No. Neither is one compound, and neither vial total belongs to one peptide. A blend’s milligram figure is shared out between its components, so a vial listed at one total holds noticeably less of each individual peptide than that number suggests.
That is why the composition table above is the useful comparison, and why the vial total on its own is not.
What Research Exists on GLOW and KLOW Themselves?
None. No published study has tested GLOW or KLOW as supplied. The research that exists is on the individual peptides, studied one at a time, in animal and cell models that were not investigating a blend.
Two of the four components have at least been examined side by side in the preclinical literature, which is more than can be said for the blend as a whole. Nothing published examines GHK-Cu or KPV in that pairing, and nothing published examines GLOW or KLOW as supplied. BPC-157 vs TB-500 sets the two molecules against each other by structure and research field.
What Has Each Component Been Studied For?
Each peptide sits in a distinct research field and carries a distinct limit. The right-hand column is the one to read: it says where each body of evidence stops.
| Peptide | Studied in relation to | Where the evidence stops |
|---|---|---|
| GHK-Cu | Extracellular-matrix research, in cell culture, where it is handled as a copper-binding tripeptide | Cell culture and tissue models, much of it review and mechanism work from a small number of groups |
| BPC-157 | Angiogenesis and cell-migration research, in preclinical models, as a fifteen-amino-acid gastric peptide sequence | Animal work, across a wide range of tissues. It is not an approved medicine anywhere |
| TB-500 | Cell-migration research, through its binding to actin, the protein cells build their internal scaffold from | Most published work is on the full thymosin beta-4 protein rather than on this seven-amino-acid fragment |
| KPV | Inflammatory-signalling research, in cell-culture and preclinical models, as a substrate of the PepT1 transporter | Cell-culture and preclinical models only. It is not evidence about a whole tissue, and not evidence about a person |
How Does Adding KPV Change What KLOW Covers?
No published work compares the two blends, so there is nothing to answer that with. KPV adds a fourth peptide with its own separate literature and its own research field; what it does not add is any tested property of the blend, because the blend itself has never been studied either way.
What can be said is narrower and more useful. The published work on KPV sits in inflammation rather than structural repair, so a four-peptide vial spans two research fields where a three-peptide vial spans one. Whether that breadth is worth anything depends entirely on what is being investigated, and it is not a question a supplier can answer.
Which Blend Holds More Material?
KLOW holds the larger vial. It is formulated to 80 mg against GLOW’s 70 mg, a difference of 10 mg, and that difference is the extra component rather than more of the peptides both vials share.
| Blend | Peptides in the vial | Total peptide per vial |
|---|---|---|
| GLOW | 3 | 70 mg |
| KLOW | 4 | 80 mg |
More total material is not the same as more of what both vials have in common, which is the comparison that usually matters. Set the totals against the composition table rather than reading either alone.
How Do You Read a Blend Certificate?
A blend certificate answers a different question from a single-peptide one, and the difference catches people out. For one compound the laboratory reports a purity percentage. For a vial holding several, it identifies each component and states the amount found — and commonly issues no purity figure at all.
ARP publishes a certificate against the GLOW listing, and it is a useful worked example because of what it leaves out. The document identifies each component and states the amount found, and reports no purity percentage at all — which is the correct outcome for a multi-peptide vial rather than a gap in the testing. It is published in the certificate library, and the name of the laboratory is printed on the document itself. No certificate is published against the KLOW listing at present.
The GLOW and KLOW Listings
Australian Research Peptides lists both blends, and the panel below is read from the catalogue rather than written by hand. Each listing remains the authority on its own vial.
| Blend | Vial | Price | Availability today | Certificate |
|---|---|---|---|---|
| GLOW | 70 mg | $189.99 | In stock | Published |
| KLOW | 80 mg | $189.99 | Out of stock | Not yet published |
Every peptide in either blend is catalogued on its own as well, so a blend can be set against its own parts without leaving the site. The stock code on each listing — 64918 and 92659 — is what ties a listing, an order line and a vial together.
Blend, or the Components Separately?
A blend fixes the ratio and leaves one vial to prepare instead of several; separate vials keep each peptide independent. Between GLOW and KLOW there is a third route, because the peptide that separates them is catalogued on its own.
That makes the choice unusually clean. Research needing the three-part combination takes GLOW. Research needing inflammation work alongside it can take the four-part vial, or hold the components apart and vary them independently. Drying four peptides into one cake is convenient precisely because it removes that freedom. Peptide types, categories and blends works through the general trade-off.
Related Guides
- BPC-157 vs TB-500: what is the difference? — the two cell-signalling peptides both blends contain, compared by sequence, structure and research field
- Peptide types, categories and blends — how blends work as a format, and when separate vials suit better
- GHK-Cu: the copper peptide and what the research shows — the largest component by mass in both blends
- Peptide testing, purity and certificates of analysis — what a certificate proves, and what it does not
- Lyophilised peptides: storage and handling — why both blends arrive as a dry cake
Both blends sit in Australian Research Peptides’ catalogue alongside every peptide they contain — GLOW as the three-part vial and KLOW as the four-part one, with GLOW on the shelf today and KLOW not, posted from Sydney to any Australian state or territory.
Read this article as plain text — GLOW vs KLOW: What Is the Difference Between the Peptide Blends?, in Markdown — the full text in Markdown, without the page around it, for assistants, screen readers and offline reading.